A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

NCT03201965 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

416

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis

Interventions

DRUG: Cyclophosphamide
DRUG: Bortezomib
DRUG: Dexamethasone, 40 mg
DRUG: Daratumumab

Sponsor

Janssen Research & Development, LLC